At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: How People With Mild Cognitive Impairment Can Read the FDA Headline Carefully

Compare at-home Leqembi shots and IV infusions on dose, safety checks, and cost before you talk to your doctor.

After the July 2026 FDA decision, people with mild cognitive impairment due to Alzheimer's can start Leqembi at home or by IV infusion. Leqembi, an antibody drug that clears amyloid protein from the brain, offers the same starting goal by either route, but at-home shots do not remove clinic safety checks. The headline means choice of delivery, not a new patient group or a clinic-free treatment. Reading carefully helps families ask about eligibility, dosing, monitoring, and cost before assuming at-home fits them.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

Who can consider Leqembi?

Treatment is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's. A test must confirm amyloid in the brain, matching the people studied in trials.

That limit matters because memory loss has many causes. People with moderate or severe dementia were not the studied group, according to Drugs.com in the FDA approval history.

How do at-home shots and IV infusions compare?

At-home initiation is 500 mg once weekly, given as two back-to-back 250-mg autoinjector shots. Each shot takes about 15 seconds, Eisai and Biogen reported in the FDA approval notice.

IV initiation is weight-based at 10 mg/kg infused over about one hour every two weeks. Eisai reported that weekly shots reached similar drug exposure as IV dosing, supporting similar amyloid removal and clinical benefit.

What happens after 18 months of starting treatment?

After 18 months of initiation dosing, patients have options. They may stay on initiation dosing or change to 360 mg weekly by subcutaneous maintenance.

Patients may also switch between IV and subcutaneous routes. That flexibility lets families and doctors adjust for travel, vein access, tolerance, and caregiver support.

What clinic care does at-home treatment still require?

Leqembi carries a boxed warning for ARIA, a term for brain swelling or tiny bleeds seen on imaging. Genetic testing for ApoE epsilon-4 and a recent baseline brain MRI are required before starting.

At-home use does not end imaging or supervision. Experts cited by Medscape stress continued MRI checks, training, first-dose oversight, and fast symptom review in the home-treatment analysis.

  • Ask when MRIs are scheduled and who reads them urgently
  • Confirm who gives the first dose and watches for reactions
  • Write down warning symptoms and the clinic's after-hours number
  • Review other blood thinners, falls, and transport plans

What does the at-home start cost?

Initiation launched through specialty pharmacy in late August 2026. The list price is $385 per autoinjector, or $770 per weekly initiation dose, as reported by Managed Healthcare Executive in the launch price report.

Eisai offers copay and patient-assistance programs. Ask the clinic's access team to check insurance rules, prior approval needs, and MRI and visit fees alongside drug cost.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.